Breast Cancer

Latest News


CME Content


The PD-L1 inhibitor MPDL3280A demonstrated a 19% objective response rate (ORR) with 75% of responses ongoing in pretreated patients with metastatic triple-negative breast cancer (TNBC), according to findings from an ongoing phase I study presented at the 2015 AACR Annual Meeting.

In this roundtable, representatives from Sharsheret, the Cancer Support Community, the Young Survival Coalition, and Living Beyond Breast Cancer discuss the impact of metastatic breast cancer.